Phase II proof-of-concept trial of a fixed-dose combination of bacitracin/tranexamic acid (IPI-120) for wound closure in dialysis patients.

Trial Profile

Phase II proof-of-concept trial of a fixed-dose combination of bacitracin/tranexamic acid (IPI-120) for wound closure in dialysis patients.

Planning
Phase of Trial: Phase II

Latest Information Update: 25 Nov 2013

At a glance

  • Drugs Antibacterials (Primary)
  • Indications Wound infections; Wounds
  • Focus Therapeutic Use
  • Sponsors Imprimis Pharmaceuticals
  • Most Recent Events

    • 25 Nov 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top